查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046172

神經生物標記市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、最終用戶、地區和競爭對手分類，2021-2031年

Neurological Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Type, By Application, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球神經生物標記市場預計將從 2025 年的 88.1 億美元大幅成長至 2031 年的 141.2 億美元，複合年成長率為 8.18%。

神經生物標記，包括存在於體液和組織中的生物分子以及影像學指標，在神經系統疾病的診斷、後續觀察和預後評估中至關重要。這一市場成長的主要驅動力是全球人口的快速老化以及由此導致的神經退化性疾病的增加，這些疾病需要有效且非侵入性的診斷工具。這些疾病負擔的加重使得早期療育和準確的患者分類變得尤為迫切。例如，阿茲海默症協會在2025年報告稱，約有720萬65歲及以上的美國人將患有老年失智症失智症，這凸顯了在推進臨床決策和治療方法對可靠生物標記的巨大需求。

市場概覽
預測期 2027-2031
市場規模：2025年 88.1億美元
市場規模：2031年 141.2億美元
複合年成長率：2026-2031年 8.18%
成長最快的細分市場 影像
最大的市場 北美洲

然而，該市場面臨的主要挑戰在於開發和檢驗這些生物標記所需的高成本和複雜性。中樞神經系統的生理保護屏障常常阻礙穩定周邊指標的識別，導致研究週期延長和監管流程更加嚴格。這些財務和技術障礙會抑制投資，延緩新診斷檢測方法的上市，並最終減緩整體市場成長。

市場促進因素

基因組學和蛋白​​質組學的技術突破正在從根本上改變全球神經生物標記市場，尤其是高靈敏度血液生物標記的開發。這些非侵入性診斷方法相比傳統的腦脊髓液分析和PET影像具有顯著優勢，從而加速了早期診斷和患者篩檢。例如，Quest Diagnostics在2025年10月發表於《神經病學臨床實踐》（Neurology Clinical Practice）的一份報告中宣布，其用於阿茲海默症的創新血液檢測組合在識別有症狀患者的澱粉樣蛋白病變方面展現出91%的靈敏度和91%的特異性。這種高精度的診斷方法能夠實現大規模且便捷的檢測，從而在臨床環境中廣泛應用，並顯著擴大市場覆蓋範圍。這些進步帶來的營運效率提升也推動了其應用。 Quest Diagnostics在2025年進行的一項調查發現，94%的受訪醫生認為，與腰椎穿刺等侵入性操作相比，這些血液檢測對醫療保健系統而言更具成本效益。

公共和私人機構對神經科學研究的投入大幅增加是推動市場發展的第二個關鍵因素，為推動從生物標記發現到商業化的複雜流程提供了必要的資金。建立可靠的神經系統疾病指標需要耗費大量資源來克服血腦障壁等生理障礙，並遵守嚴格的監管標準。根據《The Transmitter》雜誌2025年11月發布的出版報告《建立基準：2008年至2024年美國國立衛生研究院神經科學研究資助趨勢》，美國國立衛生研究院（NIH）在2024年為神經科學相關項目撥款105億美元，是2008年撥款金額的兩倍多。這種持續的投資對於維持強大的臨床研發管線至關重要，它使研究機構和診斷公司能夠檢驗新的靶點，並促進神經生物計量學領域的持續成長。

市場挑戰

生物標記的檢驗涉及大量資金投入和技術複雜性，這是限制全球神經元生物標記市場發展的主要瓶頸。由於生理屏障的存在，識別穩定的周邊指標極為困難，且必須進行長期、昂貴的臨床試驗才能滿足嚴格的監管要求。這些高昂的研發成本顯著提高了診斷公司的准入門檻，並大幅增加了其財務風險，導致公司在開發新產品時猶豫不決。因此，新檢測方法的商業化經常被推遲或取消，直接阻礙了產生收入，並限制了先進診斷工具的普及。

鑑於這些生物標記旨在緩解的神經退化性疾病帶來的日益沉重的經濟負擔，研發能力的放緩是一個特別嚴重的問題。阿茲海默症協會預測，到2025年，照顧阿茲海默症和其他失智症患者的總成本將達到3,840億美元。如此巨額的資金表明市場對有效的早期檢測工具有著極高的需求，但研發過程中巨大的資金和技術障礙阻礙了該行業的規模化發展，使其無法滿足這一迫切需求，從而抑制了整體市場的成長。

市場趨勢

隨著穿戴式科技和透過感測器整合數位生物標記的進步，持續的、真實世界的病患監測正成為可能，從根本上改變了全球神經生物標記市場。與間歇性的臨床評估（通常無法捕捉神經退化性疾病症狀的變異性）不同，基於感測器的平台能夠提供客觀的、長期的數據流，從而改善疾病管理並提高臨床試驗的效率。這一趨勢正在推動精準神經病學解決方案的普及，這些解決方案結合了被動監測和護理管理，從而顯著改善患者的治療效果。例如，Rune Labs 於 2025 年 3 月宣布，其 StrivePD Guardian 平台透過實現預防性症狀管理，使帕金森氏症患者的急診就診次數減少了 50%。這種可衡量的臨床效益正在加速數位生物標記的商業性化應用，使其成為治療方法創新和基於價值的醫療體系中不可或缺的工具。

同時，伴隨診斷在神經退化性疾病治療領域的成長正推動市場進入新一輪擴張，主要得益於需要精準患者篩檢的緩解疾病療法的核准。隨著製藥公司推出針對特定疾病（例如BETA-澱粉樣蛋白和Tau）的創新療法，基層醫療機構對便捷易用且獲得監管部門核准的篩檢工具的需求日益成長。這一轉變將使複雜的檢測從專業機構轉移到更廣泛的社區醫療機構，從而確保快速識別適合治療的患者。 2025年10月，羅氏宣布其Elecsys pTau181檢測已獲得FDA核准，這是第一個核准用於基層醫療的血液生物標記檢測，可用於排除有症狀患者的阿茲海默症病理。這項監管成就凸顯了伴隨診斷在引入新型神經系統藥物和擴大潛在患者群體方面發揮的關鍵作用。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球神經生物標記市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（成像、蛋白質體學、基因組學、代謝體學、其他）
    • 依應用領域（多發性硬化症、阿茲海默症、泛自閉症障礙、帕金森氏症等）
    • 按最終使用者（研究機構、醫院和醫院檢查室、獨立臨床診斷中心、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美神經生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲神經生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區神經生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲神經生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲神經生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球神經生物標記市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • PERKINELMER INC.
  • Abbott Laboratories Inc
  • Thermo Fisher Scientific, Inc.
  • Banyan Biomarkers, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. HOFFMANN-LA ROCHE LTD.
  • Merck & Co., Inc.
  • DiaGenic ASA
  • Johnson & Johnson Services, Inc.
  • Myriad Genetics, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17575

The Global Neurological Biomarkers Market is projected to expand significantly, rising from USD 8.81 Billion in 2025 to USD 14.12 Billion by 2031, demonstrating an 8.18% Compound Annual Growth Rate. Neurological biomarkers, which include biological molecules or imaging indicators present in bodily fluids or tissues, are crucial for diagnosing, monitoring, and assessing the prognosis of nervous system disorders. This market growth is primarily driven by a rapidly aging global population and a corresponding increase in neurodegenerative conditions, which demand effective and noninvasive diagnostic tools. The escalating burden of these diseases creates a pressing need for early intervention and precise patient categorization. For example, in 2025, the Alzheimer's Association reported approximately 7.2 million Americans aged 65 and older were living with Alzheimer's dementia, highlighting the immense requirement for reliable biomarkers in clinical decision-making and therapeutic advancement.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 8.81 Billion
Market Size 2031USD 14.12 Billion
CAGR 2026-20318.18%
Fastest Growing SegmentImaging
Largest MarketNorth America

However, a major challenge for the market is the substantial cost and complexity involved in developing and validating these biomarkers. The central nervous system's physiological protective barriers often hinder the identification of stable peripheral indicators, resulting in extended research timelines and demanding regulatory processes. These financial and technical obstacles can discourage investment and postpone the market introduction of new diagnostic assays, consequently slowing the overall growth of the market.

Market Driver

Technological breakthroughs in genomics and proteomics are fundamentally transforming the Global Neurological Biomarkers Market, notably through the development of highly sensitive blood-based biomarkers. These non-invasive diagnostic options offer significant advantages over conventional cerebrospinal fluid analysis and PET imaging, thereby accelerating early diagnosis and patient screening. For example, Quest Diagnostics reported in October 2025 that their innovative blood-based test panel for Alzheimer's disease demonstrated 91% sensitivity and 91% specificity in identifying amyloid pathology in symptomatic individuals, as published in 'Neurology Clinical Practice'. Such precise diagnostics enable scalable and accessible testing for widespread clinical deployment, substantially broadening the market reach. The operational efficiency derived from these advancements is also boosting adoption; in 2025, Quest Diagnostics found that 94% of surveyed physicians considered these blood tests more cost-effective for the healthcare system than invasive procedures like lumbar punctures.

A significant increase in public and private funding for neuroscience research constitutes the second crucial market driver, supplying the essential capital needed to navigate the intricate process from biomarker discovery to commercialization. The creation of reliable indicators for nervous system disorders demands extensive resources to overcome physiological obstacles, such as the blood-brain barrier, and to adhere to rigorous regulatory benchmarks. According to The Transmitter's November 2025 report, 'Establishing a baseline: Trends in NIH neuroscience funding from 2008 to 2024', the National Institutes of Health allocated $10.5 billion to neuroscience-related projects in 2024, representing more than double the funding levels from 2008. This consistent financial investment is vital for maintaining robust clinical pipelines, empowering research institutions and diagnostic firms to validate new targets that will fuel the sustained growth of the neurological biomarkers sector.

Market Challenge

The significant capital investment and technical complexities inherent in biomarker validation present a major constraint on the Global Neurological Biomarkers Market. The process of identifying stable peripheral indicators is made difficult by physiological barriers, mandating prolonged and expensive clinical studies to satisfy strict regulatory requirements. These high development costs establish substantial entry barriers and considerably amplify financial risks for diagnostic companies, often resulting in a hesitant approach to new product ventures. Consequently, the commercialization of novel assays is frequently postponed or cancelled, which directly impedes revenue generation and restricts the availability of advanced diagnostic tools.

This slowdown in developmental capacity is especially critical considering the growing economic burden of neurodegenerative conditions that these biomarkers are intended to alleviate. The Alzheimer's Association projected in 2025 that the total cost for caring for individuals with Alzheimer's and other dementias would reach $384 billion. Although this substantial amount underscores the immense market demand for effective early detection tools, the prohibitive financial and technical hurdles in their creation prevent the industry from adequately scaling to address this urgent need, thereby hindering overall market expansion.

Market Trends

The increasing integration of digital biomarkers through wearable technologies and sensors is fundamentally transforming the Global Neurological Biomarkers Market by facilitating continuous, real-world patient monitoring. Unlike intermittent clinical assessments, which often miss the fluctuating nature of symptoms in neurodegenerative disorders, sensor-based platforms provide objective, long-term data streams that improve disease management and enhance the efficiency of clinical trials. This trend is fostering the adoption of precision neurology solutions that combine passive monitoring with care management, leading to significantly better patient outcomes. For instance, Rune Labs announced in March 2025, concerning their StrivePD Guardian platform, that the technology resulted in a 50% reduction in emergency room visits for Parkinson's disease patients by enabling proactive symptom management. This measurable clinical benefit is accelerating the commercial adoption of digital biomarkers, establishing them as vital tools for both therapeutic innovation and value-based care frameworks.

Concurrently, the growth of companion diagnostics for neurodegenerative therapies is inaugurating a new phase of market expansion, propelled by the approval of disease-modifying treatments that necessitate accurate patient identification. As pharmaceutical firms launch innovative therapies targeting specific pathologies such as amyloid-beta and tau, there is a rising demand for accessible, regulatory-approved screening tools in primary care environments. This shift decentralizes complex testing from specialized facilities to broader community practices, ensuring that suitable patients are quickly identified for treatment. Roche reported in October 2025 that the FDA cleared their Elecsys pTau181 assay, marking it as the first blood-based biomarker test approved for use in primary care to help exclude Alzheimer's pathology in symptomatic patients. This regulatory achievement highlights the crucial role of companion diagnostics in implementing new neurological drugs and broadening the patient population that can be addressed.

Key Market Players

  • PERKINELMER INC.
  • Abbott Laboratories Inc
  • Thermo Fisher Scientific, Inc.
  • Banyan Biomarkers, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. HOFFMANN-LA ROCHE LTD.
  • Merck & Co., Inc.
  • DiaGenic ASA
  • Johnson & Johnson Services, Inc.
  • Myriad Genetics, Inc.

Report Scope

In this report, the Global Neurological Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neurological Biomarkers Market, By Type

  • Imaging
  • Proteomic
  • Genomic
  • Metabolomic
  • Others

Neurological Biomarkers Market, By Application

  • Multiple Sclerosis
  • Alzheimer's Disease
  • Autism Spectrum Disorder
  • Parkinson's Disease
  • Others

Neurological Biomarkers Market, By End-User

  • Research Organizations
  • Hospital & Hospital Laboratories
  • Independent Clinical Diagnostic Centers
  • Others

Neurological Biomarkers Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neurological Biomarkers Market.

Available Customizations:

Global Neurological Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neurological Biomarkers Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Imaging, Proteomic, Genomic, Metabolomic, Others)
    • 5.2.2. By Application (Multiple Sclerosis, Alzheimer's Disease, Autism Spectrum Disorder, Parkinson's Disease, Others)
    • 5.2.3. By End-User (Research Organizations, Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Neurological Biomarkers Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Neurological Biomarkers Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada Neurological Biomarkers Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico Neurological Biomarkers Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End-User

7. Europe Neurological Biomarkers Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Neurological Biomarkers Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End-User
    • 7.3.2. France Neurological Biomarkers Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End-User
    • 7.3.3. United Kingdom Neurological Biomarkers Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End-User
    • 7.3.4. Italy Neurological Biomarkers Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Neurological Biomarkers Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End-User

8. Asia Pacific Neurological Biomarkers Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Neurological Biomarkers Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End-User
    • 8.3.2. India Neurological Biomarkers Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End-User
    • 8.3.3. Japan Neurological Biomarkers Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End-User
    • 8.3.4. South Korea Neurological Biomarkers Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia Neurological Biomarkers Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End-User

9. Middle East & Africa Neurological Biomarkers Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Neurological Biomarkers Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End-User
    • 9.3.2. UAE Neurological Biomarkers Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End-User
    • 9.3.3. South Africa Neurological Biomarkers Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End-User

10. South America Neurological Biomarkers Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Neurological Biomarkers Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End-User
    • 10.3.2. Colombia Neurological Biomarkers Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End-User
    • 10.3.3. Argentina Neurological Biomarkers Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Neurological Biomarkers Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. PERKINELMER INC.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Abbott Laboratories Inc
  • 15.3. Thermo Fisher Scientific, Inc.
  • 15.4. Banyan Biomarkers, Inc.
  • 15.5. Bio-Rad Laboratories, Inc.
  • 15.6. F. HOFFMANN-LA ROCHE LTD.
  • 15.7. Merck & Co., Inc.
  • 15.8. DiaGenic ASA
  • 15.9. Johnson & Johnson Services, Inc.
  • 15.10. Myriad Genetics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer